Any BP team is going to consider all options, and our management team is laser-focused on shareholder value. My impression is that they are doing everything they can to raise capital to fund clinical development as cheaply as possible given our unfortunate "low" share price, which is our capital currency. Of course "low" is in the eye of the beholder, and the general market is clearly still not convinced we are on an unassailable path to commercialization for any of our lead compounds. This is puzzling to me, but as a committed investor with several hundred thousand shares and still growing I am hardly objective, though I strive to be.
Given our pipeline status, personally I'm optimistic for 2017. I think B is good to go, P will be there with the Phase 2B, and the K verdict is not "in" because the jury just got selected for trial.
News 
Market Data 
Discover 
